ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Triethylamine → N-(4-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide

HRID 2241414
印刷

反応式

HRID 2241414 の反応式
CCN=C=NCCCN(C)C.[F:12][C:13]1[CH:18]=[CH:17][C:16]([N:19]2[C:24](=[O:25])[C:23]([C:26]([OH:28])=O)=[CH:22][CH:21]=[N:20]2)=[CH:15][CH:14]=1.[CH3:29][O:30][C:31]1[CH:65]=[CH:64][C:34]([CH2:35][N:36]2[C:40]3=[N:41][CH:42]=[CH:43][C:44]([O:45][C:46]4[CH:51]=[CH:50][C:49]([NH2:52])=[CH:48][C:47]=4[F:53])=[C:39]3[C:38]([N:54]3[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][O:62][CH3:63])[CH2:56][CH2:55]3)=[N:37]2)=[CH:33][CH:32]=1.C(N(CC)CC)C>CN(C=O)C.CCOC(C)=O>[CH3:29][O:30][C:31]1[CH:32]=[CH:33][C:34]([CH2:35][N:36]2[C:40]3=[N:41][CH:42]=[CH:43][C:44]([O:45][C:46]4[CH:51]=[CH:50][C:49]([NH:52][C:26]([C:23]5[C:24](=[O:25])[N:19]([C:16]6[CH:15]=[CH:14][C:13]([F:12])=[CH:18][CH:17]=6)[N:20]=[CH:21][CH:22]=5)=[O:28])=[CH:48][C:47]=4[F:53])=[C:39]3[C:38]([N:54]3[CH2:59][CH2:58][N:57]([CH2:60][CH2:61][O:62][CH3:63])[CH2:56][CH2:55]3)=[N:37]2)=[CH:64][CH:65]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 4

HCID 8471TriethylamineHCID 159081-Ethyl-3-(3'-dimethylaminopropyl)carbodiimideHCID 667671712-(4-Fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylic acidHCID 685138364-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorobenzenamine

生成物 1

HCID 68513921
N-(4-(1-(4-methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide
収率 10%

試薬・触媒・溶媒 2

HCID 6228Dimethylformamide溶媒HCID 8857Ethyl Acetate溶媒

実験手順

EDCI (27 mg, 0.14 mmol) was added to a stirred mixture of 2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (11 mg, 0.047 mmol, prepared according to the procedure described for Example 19, Step C) and HOBt-hydrate (22 mg, 0.14 mmol) in DMF (0.3 mL) at ambient temperature, and the reaction mixture was stirred for 15 minutes at ambient temperature. 4-(1-(4-Methoxybenzyl)-3-(4-(2-methoxyethyl)piperazin-1-yl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorobenzenamine (12 mg, 0.024 mmol) and triethylamine (0.020 ml, 0.14 mmol) were then added, and the resulting mixture was stirred for 18 hours at ambient temperature. The reaction mixture was diluted with EtOAc and washed with water. The aqueous phase was re-extracted with EtOAc. The combined organic phases were washed with water, dried (Na2SO4), filtered, and concentrated in vacuo. The crude material was purified by preparative TLC (0.5 mm) and eluted with 15% MeOH/DCM (Rf=0.74). The product was obtained as a waxy solid (2 mg, 10%).

後処理

  1. customprepared
  2. customat ambient temperature
  3. stirringthe resulting mixture was stirred for 18 hours at ambient temperature
  4. washwashed with water
  5. extractionThe aqueous phase was re-extracted with EtOAc
  6. washThe combined organic phases were washed with water
  7. dry with materialdried (Na2SO4)
  8. filtrationfiltered
  9. concentrationconcentrated in vacuo
  10. customThe crude material was purified by preparative TLC (0.5 mm)
  11. washeluted with 15% MeOH/DCM (Rf=0.74)

出典と根拠

ORDレコード
ord-d3bbcb1bc4b34aa192ee2fb316c6ad56
出典データセット
uspto-grants-2010_05
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07723330B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート